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Abstract
Nausea and vomiting are chemotherapy adverse events that influence breast cancer
patient’s quality of life. Antiemetic regimen as premedication was given to prevent those
adverse events and need to be evaluated. This study aimed to present the effectiveness
of antiemetic treatment among breast cancer patients in the inpatient unit, Rumah Sakit
Umum Pusat Dr. Sardjito [Central Public Hospital Dr. Sardjito] Yogyakarta, Indonesia.
A cohort study was used in this study during July 2008 to January 2009. Thirty-one
breast cancer patients, who are receiving antiemetic therapy and having no disease
that induced nausea and vomiting were involved, signed informed consent and had
been followed by before-post chemotherapy. The data was gained from chemotherapy
and antiemetic regimens, medical records, patient’s interviews, and finally analyzed
using descriptive, evaluative approach. This study presented that antiemetic treatment
among breast cancer patient in the inpatient unit was 61.40 % ineffective reducing
incidence of nausea vomiting events. The majority of cases of nausea and vomiting
onset among patients were acute-delayed (56.2 %; 52.0 %), severity of nausea and
vomiting laid mostly in the second level (54.54 %; 52.00 %), and appropriateness
antiemetic treatment complied to NCCN guideline 2007 and ASCO guideline 2006
was only applied in low emetic risk of chemotherapy-induced nausea and vomiting.
Antiemetic regimens that had been implemented need to be evaluated because of
majority cases of nausea and vomiting were the acute-delayed type, level two of
severity and inappropriateness of international guideline. This study should be followed
with the future study of the evaluation of the effectiveness of another medication
supported the patient in receiving chemotherapy.
Keywords: Antiemetic, Breast cancer, Effectiveness, Nausea, Vomiting.
1. Introduction
About 7 600 000 from 58 000 000 people died caused by cancer, and 70 % of them
lived in low-middle income countries with minimum prevention, therapy availability, and
accessibility. The number of death caused by cancer projected increasing by 11 400 000
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in 2030. In Indonesia, breast cancer was lied together in five top highest rank cancer
case among women [1, 2].
Chemotherapy is selected as the main therapy for treated breast cancer [3, 4]. Nausea
and vomiting are the adverse effects of chemotherapy that frequently reported and
negatively affected patients, especially in their daily life, the quality of life of patients
and the adherence to chemotherapy. Uncontrolled nausea vomiting would lead to the
worsen patient’s condition, decreased patient’s appetite, poor nutritional status, dehy-
dration, electrolyte disturbances and pneumonia [5]. To overcome it, patient in under-
going chemotherapy commonly used antiemetic as prophylaxis [6].
Based on the data above, the treatment of nausea and vomiting among patients
with breast cancer need to be evaluated especially the effectiveness of its therapy for
supporting the quality life of patients. So, assessing the effectiveness of nausea and
vomiting treatment is very important, to know the extent to which the management
of these therapies successfully implemented and to see the treatment will bring great
benefit to the patients or not.
2. Methods
This study aimed to present the effectiveness of antiemetic treatment among breast
cancer patients in the inpatient unit, Rumah Sakit Umum Pusat – RSUP Dr. Sardjito
(Central Public Hospital Dr. Sardjito) Yogyakarta, Indonesia. Central Public Hospital Dr.
Sardjito Yogyakarta was chosen as study location because it is one of referral hospital
for cancer in Indonesia, especially in Central Java Province and D.I. Yogyakarta Province.
Breast cancer was in the second top rank of cases in this hospital from 2003 to 2004
[7].
All respondents were breast cancer patients who voluntarily recruited during July
2008 to January 2009 and met the inclusion criteria such as (i) receiving antiemetic
therapy, (ii) having no disease that induced nausea and vomiting, (iii) signed informed
consent, (iv) having completed medical records, chemotherapy protocols, and (v) having
willingness to be interviewed. About 55 patients (110 cases) were obtained and signed
informed consent, only 31 patients (57 cases) were enrolled with completed data.
This study used a cohort study with descriptive evaluation approach. The data
was gained prospectively. The instruments of this study were semi-structured inter-
view protocols, Card of Patient’s Medication (KIPO), informed consent, chemotherapy
protocols, and patient’s medical records. The effectiveness of antiemetic regimens
DOI 10.18502/kls.v4i11.3847 Page 9
UASC Life Sciences 2016
was evaluated by comparing the level of emetic severity between pre- and post-
chemotherapy. Antiemetic regimens also evaluated with the appropriateness to the
ASCO (2006) guideline and NCCN (2007) guideline.
Ethical clearance (KE/FK/208/EC) – the approval to conduct this study – was obtained
from the UGM ethical committee, and permission (LB.02.01.4.9082-2) was granted from
RSUP Dr. Sardjito. Written-informed consent was obtained from all of the participants
who agreed to participate in the study. Participants were also assured of the confiden-
tiality of their identity.
The strength of the study could describe the pattern of antiemetic therapy and
showed the effectiveness of antiemetic regimens to prevent nausea and vomiting among
breast cancer patients. The limitations of this study were [1] the study was conducted
from July 2008 to January 2009, need more extended duration of the program; [2]
incomplete data pre and post-chemotherapy due to inconsistence patient’s treatment
schedule. It made 26 patients who potential and having a willingness to join this study
failed to be followed up.
55 patients 
(110 cases) 
43 patients  
(91 cases) 
8 patients  
 
8 patients failed to be known 
their chemotherapy protocols 
and/or their antiemetic 
premedication 
31 patients 
 (57 cases) 
18 patients 
  
5 patients failed to be 
interviewed 
13 patients failed to be 






Figure 1: Flow Chart of Patients who recruited in this study.
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3. Results
Breast cancer patients received various chemotherapy regimens (low, moderate, and
high emetic chemotherapy agents) in four or six cycles. All of them were women (100
%), with majority 50 yr to 59 yr (45.2 %). It was relevant with data from Canadian Cancer
Statistics in 2007 [8]. Most of them were menopause (83.9 %) and in the advance stages
of cancer (81.2 %). This fact appeared due to the delayed diagnosis of cancer. Mostly,
the patient got anemia in the second cycle of their chemotherapy treatment (13.46 %).
This hematology complication affected the type and duration of therapy and malignant
stages due to the decision having a blood transfusion. The family history of breast cancer
patients have been traced, only five patients (16.13 %) showed that their mother or sister
who died because of cancer.
Table 1: Characteristics of breast cancer patients who received chemotherapy in inpatient unit, Central Public
Hospital Dr. Sardjito July 2008 to January 2009.
Characteristics n (n=31) Percentage (%)
Age
30 yr to 39 yr 3 9.68
40 yr to 49 yr 12 38.71
50 yr to 59 yr 14 45.16
60 yr to 69 yr 1 3.23
















<12 yr 0 0.00
12 yr to 14 yr 14 45.16
>14 yr 4 12.90
Not Remember/Not Known 13 41.94
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Metoclopramide, antagonist dopamine-2 (26.82 %) was used as antiemetic premed-
ication among patient who got chemotherapy regimens with low emetic risk. Mostly,
metoclopramide as single medication (10 cases) blocked dopamine-2 receptor to pre-
vent nausea and vomiting: dexamethasone (25.7 %) and diphenhydramine (18.8 %) com-
monly used as a combination with antagonist dopamine-2 or antagonist 5HT-3 receptor.
Table 2: Chemotherapy and antiemetic regimens therapy variation in inpatient unit, Central Public Hospital
Dr. Sardjito July 2008 to January 2009.
Medication N (31 Patients, 57 cases) (%)
Cycle
First Cycle 50 87.72
Second Cycle 7 12.28
Cancer Regimens
AC (Cyclophosphamide + Doxorubicin) 3 9.68
AT (Doxorubicin + Paclitaxel) 12 38.71
TC (Paclitaxel + Carboplatin) 14 45.16
CE (Cyclophosphamide + Ephyrubicine) 1 3.23
T (Paclitaxe) 1 3.23
Type of Antiemetic Regimens
Dopamine 2 antagonist : Metoclopramid (i.v) 47 26.86
5HT3 antagonist : Ondansetron (i.v.) 10 5.71
Corticosteroid : Dexamethasone (i.v.)/(p.o.) 44/1 25.14 / 0.57
Antihistamine : Diphenhydramine (i.v.) /(i.m..) 31/2 17.71 / 1.14
Proton Pump Inhibitor : Ranitidine (i.v.) 40 22.86
Variation of Antiemetic regimens
One drug (M /D/O) 12 (10/1/1)
Combination of two drugs (OD) 5 (5)
Combination of three drugs (MDR / ODR / ODD) 7 (5/1/1)
Combination of four drugs (ODRP / MTRP / MODR) 33 91/31/1)
Note: ODRP (Ondansetron + Dexametashone + Ondansetron + Dyphenhidramin), MTRP (Metoclo-
pramide + Dexamethasone + Ranitidine); MODR (Metoclopramide + Ondansetron + Dexamethasone
+ Ranitidine); p.o. (per oral); i.m. (intramuscular); i.v. (intravena).
All of breast cancer patients experienced nausea, vomiting, and both of events. About
61.4 % patients still perceived nausea and/or vomiting, only 38.60 % were free from
those events. See table 3. If we take a look in details, the cases of nausea-induced
chemotherapy (33 cases) were higher than vomiting-induced chemotherapy (25 cases).
The severity levels of nausea and/or vomiting were presented mostly in second level
(from 5 levels) for nausea (54.45 %) and vomiting (52.00 %).
The onset of nausea and vomiting were presented separately in 2 figures, Fig. 2.
Patients who received high emetic risk of chemotherapy regimens experienced vomit-
ing in several hours after chemotherapy in first day (acute). Low-moderate emetic risk
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Table 3: Cases of nausea and vomiting compared to the emetic risk of chemotherapy in inpatient unit,
Central Public Hospital Dr. Sardjito July 2008 to January 2009.
Potential Emetogenecity of
Chemotherapy Regiments








Low (10 % to < 30 %) 7 2 1 0 10
Low (10 % to < 30%) and
Moderate (< 30 % to 90 %)
9 5 3 10 27
High (> 90 %) 6 3 1 10 20
Total 22 10 5 20 57
Percentage (%) 38.60 17.54 8.77 35.09 100.00
Table 4: Level of severity nausea and vomiting of breast cancer patients in inpatient unit, Central Public
Hospital Dr. Sardjito July 2008 to January 2009.
Patient’s Condition Level of Severity [n (%)]
1 2 3 4 5
Nausea (n=33) 13 (39.39) 18 (54.55) 2 (6.06) 0(0.00) 0 (0.00)
Vomiting (n=25) 5 (20.00) 13(52.00) 7 (28.00) 0(0.00) 0(0.00)
Table 5: The Antiemetic regimens usage of breast cancer patients in inpatient unit, Central Public Hospital




M O D MD OD MDH ODH MOD
Low (10 % to < 30 %) T Regiments (n=10) 10
Low and Moderate
(10 % to < 30 %)
(30 % to 90 %)
AT Regiments (n=20) 1 3 16
TC Regiments (n=7) 5 2
High (> 90 %) AC Regiments (n=19) 10 1 1 6 1
CE Regiments (n=1) 1
Total 10 1 1 5 6 31 2 1
Notes: T (Paclitaxel); AT (Doxorubicine + Paclitaxel); TC (Paclitaxel + Carboplatine); AC
(Cyclophosphamide + Carboplatine); CE (Cyclophosphamide + Epirubicine); M (Metoclopramide);
O (Ondansetron); D (Dexamethasone); MD (Metoclopramide + Dexamethasone); OD (Ondansetron
+ Dexamethasone); MDH (Metoclopramide + Dexamethasone + Dyphenhydramine); ODH
(Ondansetron + Dexamethasone + Dyphenhidramine) + MOD (Metoclopramide + Ondansetron
+ Dexamethasone)
extremely induced nausea and vomiting in the first day and followed more than 5 d
(delayed).
The antiemetic, its relation of emetic risk level and chemotherapy regimens that had
been chosen presentedwell in Table 5. Patient from low to high had taken the antiemetic
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Figure 2: The onset of nausea versus vomiting compared to the level of emetogenecity of chemotherapy
regimens.
tended to be varied. In low emetic risk level of chemotherapy regimens, there is no vari-
ation of antiemetic, all patients treated with a combination of metoclopramide, dexam-
ethasone, and diphenhydramine. For low and moderate risk level, several patients got
single medication (dexamethasone), three of them got a combination of metoclopramide
and dexamethasone, and the rest of it treated with metoclopramide, dexamethasone
and diphenhydramine or ondansetron, dexamethasone and diphenhydramine. Varia-
tion of chemotherapy agents which is at high risk level was almost the same with low-
moderate risk level, but metoclopramide had been dominated as the single medication.
The emetic treatment as premedication presented was ineffective (64.92 %) reducing
the level and cases of nausea and/or vomiting-induced-chemotherapy. It strongly related
to inappropriateness with NCCN 2007 and ASCO 2006 which added as a negative
factor. Only one part of NCCN guideline that met the implementation, metoclopramide
without or with dexamethasone, diphenhydramine, and prochlorperazine.
4. Discussion
Reducing the cases of nausea and/or vomiting after chemotherapy difficult to be
attempted. Table 3 presented the number of cases and its categories. Those data
were in line with Germany cancer center study, about 62.5 % nausea events had been
recorded compared to the vomiting events which only shown about 26 % [9]. Acute
onset, delayed onset or both events of nausea and vomiting appeared clearly. It showed
that those events hardly avoided [10].
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Table 6: The effectiveness of antiemetic regimens.
Antiemetic Premedication Emetic Risk The Effectiveness of Antiemetic
Ineffective Effective Total
Metoclopramide High 5 5 10
Ondansetrone High 1 - 1
Dexamethasone Low-Moderate 1 - 1
Metoclopramide +
Dexamethasone
Low-Moderate 3 - 3
High 2 - 2
Ondansetrone +
Dexamethasone




Low 3 7 10








High 1 - 1
Total 37 20 57
Patients who got chemotherapy regimens with high emetic risks (> 90 %) tended to
experience nausea and vomiting rather than the combination of low-moderate risks (10
% to 30 %, 30 % to 90 %) and low risks regimens (10 % to 30 %). Table 5 showed that the
patients who got high emetic chemotherapy regimens (AC and CE regimens) treated
mostly with metoclopramide only (10 cases) which did not appropriate with the ASCO
or NCCN Guideline [11]. Low dose metoclopramide stimulated gastric emptying, in high
dose, metoclopramide worked to stop the stimulation to the brain which can cause nau-
sea vomiting [5]. Blocking dopamine-2 was not only enough because of the complexity
of emesis induced chemotherapy. They were undertreated and should receive a combi-
nation of antiemetic drug therapy to prevent nausea and/or vomiting. Dexamethasone,
ranitidine, and diphenhydramine are needed to be added in the antiemetic regimens
[11].
Contrary, patients who received low risks chemotherapy regimens, T regimens, (10
cases) found over-treated. The patient got a combination of antiemetic premedication,
metoclopramide, dexamethasone, and diphenhydramine. Only seven cases from 10
cases successfully reduced the level severity of nausea and vomiting events. This fact
showed that antiemetic premedication that had been provided to the patients did not
meet the therapeutic goals.
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The majority of antiemetic regimens provided in combination in order to increase the
efficacy of drugs reduced the toxicity of antiemetic therapy and preventing the adverse
effect of chemotherapy. Metoclopramide or Ondansetron combined with another
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medicine. Dexamethasone usually used in combination with high dose metoclopramide
could reduce adverse reaction of metoclopramide (diarrhea) and might affect
prostaglandin activity in the brain although the mechanism of action is not well-
understood — some of the studies mentioned its action in potentiating antiemetic
properties of 5HT3 agents [2]. Ranitidine (22.9 %) frequently needed to be added in
nausea vomiting therapy by reducing acid secretion. The cytotoxic agent could damage
gastric mucus up to gastrointestinal tract — Diphenhydramine commonly used as an
additional medication to reduce the side effect of metoclopramide, extrapyramidal
symptom [11].
All antiemetic regimens that had been provided to the breast cancer patient did not
appropriate with NCCN and ASCO guideline. The aprepitant that had been recom-
mended since 2003 was not available in Indonesia as the main reason [11, 12].
5. Conclusions
Antiemetic regimens were ineffective because of several factors, such as cases of nau-
sea and vomiting still dominants (64.91 %) with the type of onset acute-delayed, level
two of severity, and inappropriateness with NCCN (2007) standard and ASCO (2006)
standard.
This study finding will be useful for Central Public Hospital Dr. Sardjito to have better
services to breast cancer patients who are dealing with nausea and vomiting during
chemotherapy treatment.
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